References
- Babaei M, Chadegani AR, Ghadam P. (2015). Binding of topotecan to chromatin: insights into cooperative binding and comparison with DNA. Int J Biol Macromol 80:57–63
- Berna GR, Sanjuan VM, Alvarez MG, et al. (2014). A promising camptothecin derivative: semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem 83:366–73
- Botella P, Abasolo I, Fernandez Y, et al. (2011). Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. J Controlled Release 156:246–57
- Ci T, Li T, Chang G, et al. (2013). Simply mixing with poly (ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family. J Controlled Release 169:329–35
- Fichter M, Dedters M, Nguyen AP, et al. (2015). Monophosphoryl lipid a coating of hydroxyethyl starch nanocapsulesdrastically increases uptake and maturation by dendritic cells while minimizing the adjuvant dosage. Vaccine 33:838–46
- Filippov SK, Sergeeva OY, Vlasov PS, et al. (2015). Modified hydroxyethyl starch protects cells from oxidative damage. Carbohydr Polym 134:314–23
- Grillet F, Sabot C, Anderson R, et al. (2011). Intramolecular isomünchnone cycloaddition approach to the antitumor agent camptothecin. Tetrahedron 67:2579–84
- Jiang RJ, Zhao YL, Chen YJ, et al. (2014). Synthesis, characterization, and in vitro evaluation of artesunate-β-cyclodextrin conjugates as novel anti-cancer prodrugs. Carbohyd Res 400:19–25
- Kim JH, Jeong M, Lee SS, Song J. (2015). Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ. Biochem Bioph Res Co 463:1122–8
- Li GF, Cai CF, Ren TY, Tang X. (2014a). Development and application of a UPLC–MS/MS method for the pharmacokinetic study of 10-hydroxy camptothecin and hydroxyethyl starch conjugate in rats. J Pharm Biomed Anal 88:345–53
- Li GF, Li Y, Tang YL, et al. (2014b). Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin. Int J Pharm 471:234–44
- Li N, Deng Y, Wang D, et al. (2013). Determination of glibenclamide and puerarin in rat plasma by UPLC-MS/MS: application to their pharmacokinetic interaction study. Talanta 104:109–15
- Li N, Li N, Yi QY, et al. (2014). Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent. Biomaterials 35:9529–45
- Lv SX, Tang ZH, Zhang DW, et al. (2014). Well-defined polymer-drug conjugate engineered with redox and pH-sensitive release mechanism for efficient delivery of paclitaxel. J Controlled Release 194:220–7
- Maeda H. (2010). Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjugate chem 21:797–802
- Nichols JW, Bae YH. (2014). EPR: evidence and fallacy. J. Controlled Release 190:451–64
- Noga M, Edinger D, Wagner E, et al. (2014). Stability and activity of hydroxyethyl starch-coated polyplexes in frozen solutions or lyophilizates. Int J Pharm 469:50–8
- Peer D, Karp JM, Hong S, et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–60
- Shi S, Chen H, Lin X, Tang X. (2010). Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion. Int J Pharm 383:264–70
- Song L, Bevins R, Anderson BD. (2006). Kinetics and mechanisms of activation of α-amino acid ester prodrugs of camptothecins. J Med Chem 49:4344–55
- Tseng YY, Wang YC, Su CH, et al. (2015). Concurrent delivery of carmustine, irinotecan, and cisplatin to thecerebral cavity using biodegradable nanofibers: in vitro and in vivo studies. Colloids Surf B Biointerfaces 134:254–61
- Wang K, Zhang XF, Liu Y, et al. (2014). Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 35:8735–47
- Wu XW, Li HP, Song SE, et al. (2013). Facile synthesis of camptothecin intercalated layered double hydroxide nanohybrids via a coassembly route. Int J Pharm 454:453–61